rs3212227 — IL12B 3'UTR

IL12B 3'-UTR variant forming the canonical two-SNP psoriasis risk haplotype with rs6887695; T allele (coding-strand A, risk) drives 12.5-fold higher IL12B expression and substantially elevated psoriasis susceptibility; G allele is protective and predicts better ustekinumab response

See your personal result for IL12B

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IL12B 3'UTR Variant — The Canonical Psoriasis Risk SNP and Ustekinumab Response Predictor

The IL12B gene11 IL12B gene
located at 5q33.3, encodes the 40 kDa p40 subunit shared by two functionally distinct cytokines: IL-12 (p40/p35 heterodimer, drives Th1 and IFN-γ production) and IL-23 (p40/p19 heterodimer, drives Th17 expansion and IL-17 production). Both arms of this axis converge on psoriatic inflammation — IL-12/Th1 activates keratinocytes via IFN-γ while IL-23/Th17 drives epidermal hyperproliferation through IL-17. rs3212227 is a 3'-UTR variant at chr5:159315942 (GRCh38) in the IL12B gene. Because IL12B is transcribed from the minus strand, papers describe this variant using coding-strand notation as "1188A>C" — the A allele in coding-strand notation corresponds to the T allele on the plus (reference) genomic strand, which is what genome files report. The T allele (risk) is the major allele globally (~72%) and in Europeans (~80%). rs3212227 is the most widely studied SNP at the IL12B locus for psoriasis susceptibility and is the primary anchor of the canonical two-SNP risk haplotype with [rs6887695 | an upstream IL12B variant approximately 60 kb from the coding region that forms the best-characterised IL12B psoriasis haplotype together with rs3212227]. p40 is also the direct molecular target of [ustekinumab (Stelara) | a monoclonal antibody blocking both IL-12 and IL-23 simultaneously by binding their shared p40 subunit], making rs3212227 both a susceptibility marker and a pharmacogenomic predictor of biologic treatment outcome.

The Mechanism

The 3'-UTR location of rs3212227 places it in a regulatory sequence that influences IL12B mRNA stability and translational efficiency. The risk haplotype defined by rs6887695G/rs3212227T (plus-strand notation) substantially amplifies IL12B transcription. Johnston et al. 201322 Johnston et al. 2013
Susceptibility-associated genetic variation at IL12B enhances Th1 polarization in psoriasis, Journal of Investigative Dermatology demonstrated that homozygous risk carriers show on average 12.5-fold higher IL12B expression after monocyte stimulation compared to homozygous non-carriers, with approximately 6-fold elevated serum IL-12 and markedly elevated IFN-γ and the IFN-γ-induced chemokine CXCL10. Paradoxically, IL-23 levels decreased ~1.4-fold in risk carriers — this skew toward Th1 over Th17 reflects an autoregulatory feedback where excess IL-12 promotes Th1 differentiation at the expense of the Th17 arm. The net clinical effect is chronic skin inflammation driven predominantly by the IFN-γ/Th1 axis in high-IL12B-expression individuals, while lower expressors show more balanced Th1/Th17 disease. The protective G allele (plus-strand) corresponds to coding-strand C, and tags a regulatory state that restrains this IL12B amplification.

The Evidence

rs3212227 was established as the primary IL12B psoriasis susceptibility SNP by Cargill et al. 200733 Cargill et al. 2007
A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes, a landmark study of 1,446 cases and 1,432 controls across three independent white North American cohorts reporting OR 0.64 for the protective allele (Pcomb = 7.85×10⁻¹⁰). This study also described the canonical two-SNP risk haplotype with rs6887695 (OR 1.40 for the risk haplotype). The findings were replicated and extended by Nair et al. 200844 Nair et al. 2008
Polymorphisms of the IL12B and IL23R genes are associated with psoriasis in 1,810 cases and 2,522 controls plus 509 family pedigrees, yielding OR 1.62 for rs3212227 (P = 1.7×10⁻¹⁵) — among the highest effect sizes reported for any psoriasis susceptibility SNP outside the MHC. A meta-analysis of 11 studies (Zhu et al. 2013)55 meta-analysis of 11 studies (Zhu et al. 2013)
Meta-analysis of IL12B polymorphisms (rs3212227, rs6887695) with psoriasis and psoriatic arthritis confirmed OR 0.688 (95% CI 0.650–0.729) for the protective minor allele in psoriasis and OR 0.707 (95% CI 0.628–0.797) in psoriatic arthritis, with consistent signal across ethnicities.

For pharmacogenomics, Galluzzo et al. 201666 Galluzzo et al. 2016
IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction found that in HLA-Cw6 positive psoriasis patients treated with ustekinumab, the absence of the homozygous risk genotype at rs3212227 significantly increased the probability of therapeutic success. This identifies rs3212227 as a pharmacogenomic stratifier for anti-p40 biologic therapy: individuals carrying at least one protective G allele (TG or GG) show better early treatment responses to ustekinumab than TT homozygotes.

The IL12B susceptibility locus is also shared with inflammatory bowel disease. The IL-12/IL-23 pathway drives mucosal inflammation in Crohn's disease and ulcerative colitis, and IL12B variants have been consistently associated with IBD susceptibility. The same p40-targeting mechanism underlies ustekinumab's FDA approval for both moderate-to-severe plaque psoriasis and Crohn's disease.

Practical Actions

For TT homozygotes (the majority of people), the clinical relevance is twofold. For psoriasis susceptibility: TT individuals have the highest genetic load at the IL12B locus and lack the protective regulatory effect of the G allele. For pharmacogenomics: when ustekinumab is being considered for psoriasis or Crohn's disease, TT homozygotes are in the group with the least favourable early response profile — this does not rule out the drug, but argues for setting realistic expectations about early PASI response timelines and for closely monitoring treatment progress at 3 months. TG heterozygotes and GG homozygotes have incrementally better response profiles.

For carriers of the protective G allele (TG or GG), this result is actively useful: if psoriasis develops and biologic therapy is indicated, the genotype supports ustekinumab as a rational first-line choice, particularly when combined with HLA-Cw6 typing. Guselkumab and risankizumab target only the IL-23-specific p19 subunit rather than the shared p40; their response prediction is not directly influenced by rs3212227 in the same way.

The IBD connection is clinically relevant across all genotypes: TT homozygotes carrying the highest IL12B-driven inflammation risk should be aware of the psoriasis-IBD comorbidity and investigate persistent gastrointestinal symptoms.

Interactions

rs3212227 and rs6887695 together define the canonical IL12B psoriasis risk haplotype; they are the most extensively studied pair at this locus and should be considered jointly for haplotype-level risk assessment. Both are now in the GeneOps database. rs3213094 (IL12B intronic) is in partial linkage disequilibrium with rs3212227 and has independent pharmacogenomic value for ustekinumab response prediction (Galluzzo 2016); carrying risk alleles at both rs3212227 and rs3213094 marks the highest IL12B-driven psoriasis susceptibility subgroup. rs11209026 (IL23R R381Q) is a strongly protective IL-23 receptor loss-of-function variant; carriers of both the IL12B TT risk genotype and the IL23R protective A allele have a partially antagonistic combination where elevated p40 production is partially offset by reduced receptor sensitivity downstream. rs12188300 (near-gene IL12B regulatory) was identified in the same German psoriasis GWAS screen and represents an independent signal at the 5q33.3 locus.

Drug Interactions

ustekinumab dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

GG Homozygous Protective Normal

Two copies of the protective G allele — lowest psoriasis risk at this locus, best ustekinumab response profile

You carry two copies of the G allele at rs3212227 in the IL12B gene. This is the rarest genotype in European populations (approximately 4% of Europeans, but more common in East Asian and African populations at roughly 22% and 10% respectively). The G allele tags a regulatory state that substantially restrains IL12B expression. Homozygous protective carriers show 12.5-fold lower IL12B output after stimulation compared to TT homozygotes (Johnston et al. 2013), with correspondingly lower serum IL-12 and IFN-γ. The Zhu 2013 meta-analysis confirms OR 0.688 for the protective allele — GG homozygotes have the greatest protection at this locus. For biologic therapy, the Galluzzo 2016 study found that absence of the risk genotype (i.e., carrying the G allele) was the best predictor of ustekinumab therapeutic success in HLA-Cw6 positive patients.

GT Protective Allele Carrier Intermediate

One protective G allele — reduced psoriasis risk and favourable ustekinumab response profile

The TG heterozygous state produces an intermediate IL12B expression level between TT risk homozygotes and GG protective homozygotes. The 12.5-fold expression difference between TT and GG in Johnston 2013 is measured in homozygotes; TG individuals likely occupy a midpoint. This partial protection translates to measurable risk reduction in association studies, with the protective allele acting in a codominant fashion. The psoriatic arthritis association follows a similar pattern — TG carriers have intermediate joint disease risk compared to the two homozygote groups.

For biologic therapy: the Galluzzo 2016 finding specifically highlighted "absence of AA genotype" (which in plus-strand notation corresponds to absence of TT genotype) as predictive of better ustekinumab response. TG carriers fall in the favourable group. This provides actionable pharmacogenomic guidance for biologic selection conversations.

TT IL12B Risk Homozygote High Risk

Homozygous for the IL12B risk allele — highest susceptibility at this locus, attenuated ustekinumab response

The TT genotype reflects homozygosity for the regulatory state that maximally amplifies IL12B transcription. The 12.5-fold expression difference between TT and GG individuals is one of the largest cis-regulatory effects documented at this locus, explaining why rs3212227 shows such a strong statistical signal in GWAS despite being a common variant. Functionally, elevated IL12B drives enhanced Th1 polarization through IL-12/IFN-γ signaling, but paradoxically also reduces IL-23 (the shared p40 is more often incorporated into IL-12 than IL-23 dimers when overproduced), creating a Th1-dominant inflammatory environment in psoriatic skin.

For biologic therapy: ustekinumab blocks the p40 subunit encoded by IL12B. TT homozygotes have the most p40 target available for ustekinumab binding, which might seem advantageous, but the Galluzzo 2016 data show attenuated early response for individuals lacking the protective G allele. This may reflect the magnitude of the inflammatory signal exceeding what standard dosing can fully suppress at early time points. Longer treatment or dose escalation may normalize outcomes. Guselkumab (anti-p19) and risankizumab (anti-p19) target only the IL-23-specific subunit; their efficacy may be less directly influenced by IL12B expression levels.

The psoriatic arthritis association (OR ~1.4–1.6 across studies) means TT carriers with any skin psoriasis should actively monitor for joint symptoms — nail pitting, dactylitis, and inflammatory back pain are early signs that precede structural joint damage.